Comparing Obicetrapib and Bempedoic Acid for Adults with High-Risk Dyslipidemia on Maximum Lipid-Lowering Therapy

What this Trial Is About

Researchers are evaluating the effects of obicetrapib compared to bempedoic acid in adults with high or very high cardiovascular risk who have elevated low density lipoprotein cholesterol LDL-C despite receiving the strongest tolerated lipid-lowering treatments. This Phase 3 randomized, double-blind study aims to assess how well these two drugs lower LDL-C levels over a 12-week period. Participants will be randomly assigned to receive either obicetrapib 10 mg with a placebo for bempedoic acid or bempedoic acid 180 mg with a placebo for obicetrapib. Both treatments are taken orally once daily during the approximately 84-day treatment period. The study compares the LDL-C lowering effects of these two drugs while monitoring safety and tolerability. During the study, participants will have their LDL-C and other lipid levels measured at the start and after 84 days to assess changes. Additional blood tests will measure non-HDL cholesterol, HDL cholesterol, ApoA1, Lpa, ApoB, and triglycerides. Safety and side effects will also be monitored throughout the treatment period. Participants continue their usual lipid-lowering therapies during the trial.

Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days